Press Releases

Date Title    
Toggle Summary Editas Medicine Announces Third Quarter 2018 Results and Update
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight novel Sickle Cell Disease and Beta-Thalassemia program Strong balance sheet with $337 million of cash,
Toggle Summary Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 7, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the third
Toggle Summary Editas Medicine Grows Scientific Leadership with Two New Appointments
CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan , Ph.D., a leading expert in gene therapy and oncology, joins the Company as Senior Vice President of Immunogenetics. Dr.
Toggle Summary Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
CAMBRIDGE, Mass. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S.
Toggle Summary Editas Medicine Announces Transition of Chief Medical Officer
CAMBRIDGE, Mass. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox , M.D., Ph.D., will be stepping down from the Company at the end of the year.
Toggle Summary Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
CAMBRIDGE, Mass. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-101.
Toggle Summary Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
  Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that
Toggle Summary Editas Medicine Announces Second Quarter 2018 Results and Update
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101 Investigational New Drug (IND) application in October 2018 Strong balance sheet to advance Company
Toggle Summary Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass. , July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the second quarter of
Toggle Summary Editas Medicine to Participate in The JMP Securities Life Sciences Conference
CAMBRIDGE, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a panel and host investor meetings at the JMP Securities Life Sciences Conference in New York on Wednesday, June 20 , 2018. 
Toggle Summary Editas Medicine Reports Data Demonstrating Subretinal Injection of EDIT-101 Well-tolerated in Non-human Primates
Presentation at the Annual Meeting of the American Society of Gene & Cell Therapy CAMBRIDGE, Mass. , May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 was
Toggle Summary Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 , at 8 a.m.
Toggle Summary Editas Medicine Announces First Quarter 2018 Results and Update
Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of Directors with addition of James C. Mullen and Jessica Hopfield , Ph.D. Cash, cash equivalents, and marketable securities of $359 million as of March 31, 2018 CAMBRIDGE, Mass.
Toggle Summary Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Oral presentation of tolerability and immunogenicity data from a study of EDIT-101 following subretinal injection in non-human primates CAMBRIDGE, Mass. , April 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that 10 scientific
Toggle Summary Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of
Toggle Summary Editas Medicine Names James C. Mullen as Chairman of the Board of Directors
CAMBRIDGE, Mass. , March 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of James C. Mullen as Chairman of the Board of Directors, effective immediately. Mr. Mullen has more than 30 years of experience building
Toggle Summary Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update
EDIT-101 for Leber Congenital Amaurosis type 10 (LCA10) on track for mid-2018 Investigational New Drug (IND) filing Expecting at least five clinical-stage programs by end of 2022 as part of EM22 five-year goals Year-end cash, cash equivalents, and marketable securities of $329 million expected to
Toggle Summary Editas Medicine Supports Rare Disease Day® and Joins Global Movement to Raise Important Awareness for Rare Diseases
CAMBRIDGE, Mass. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the Company has joined forces with 30 million Americans and health care advocates around the world for Rare Disease Day ® today.
Toggle Summary Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results
CAMBRIDGE, Mass. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, March 6th, 2018 , at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter
Toggle Summary Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
CAMBRIDGE, Mass. , Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield , Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also serve on the Audit Committee of the
Toggle Summary Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows: BIO CEO & Investor Conference Date:   Monday, February 12, 2018 Forum:  
Toggle Summary Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first acquisition with purchase of certain assets from i2 Pharmaceuticals and its affiliates, further
Toggle Summary Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 36 th Annual J.P. Morgan Healthcare Conference on Wednesday, January
Toggle Summary Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia
Experiments support opportunities to develop best-in-class therapies for hemoglobinopathies CAMBRIDGE, Mass. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome
Toggle Summary Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 06, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares of its common stock. The gross proceeds to Editas Medicine from this offering are expected to be
Toggle Summary Editas Medicine, Inc., Announces Offering of Common Stock
CAMBRIDGE, Mass. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of its common stock in an underwritten public offering.
Toggle Summary Editas Medicine Announces Third Quarter 2017 Results and Update
CAMBRIDGE, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30, 2017 , and provided an update on recent achievements and upcoming events.
Toggle Summary Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results
CAMBRIDGE, Mass. , Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday, November 7, 2017 , at 5:00 p.m. ET to discuss a corporate update and results for the third quarter
Toggle Summary Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice
Productive gene editing rates with EDIT-101 were stable over six months in transgenic mice CAMBRIDGE, Mass. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study in transgenic mice demonstrating
Toggle Summary Editas Medicine to Participate in Investor Conferences in October
CAMBRIDGE, Mass. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October.  Details are as follows: Chardan Gene Therapy Conference Tuesday,
Toggle Summary Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)
Toggle Summary Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
Toggle Summary Editas Medicine Announces Second Quarter 2017 Results and Update
Toggle Summary Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment
Toggle Summary Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
Toggle Summary Editas Medicine to Participate in Investor Conferences in June
Toggle Summary Editas Medicine Names Andrew Hirsch to Board of Directors
Toggle Summary Editas Medicine Announces First Quarter 2017 Results and Update
Toggle Summary Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
Toggle Summary Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
Toggle Summary Editas Medicine to Present at Investor Conferences in May
Toggle Summary Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
Toggle Summary Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
Toggle Summary Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock
Toggle Summary Editas Medicine, Inc., Announces Proposed Offering of Common Stock
Toggle Summary Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases
Toggle Summary Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
Toggle Summary Editas Medicine Announces Departure of Chief Operating Officer
Toggle Summary Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results
Toggle Summary Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017
Toggle Summary Editas Medicine to Present at Investor Conferences in March
Toggle Summary Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference
Toggle Summary Editas Medicine to Present at Upcoming February Investor Conferences
Toggle Summary Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference
Toggle Summary Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference